The significance of lower extremity FDG PET/CT imaging in patients with unknown primary tumor

Yıl 2015, Cilt: 2 Sayı: 6, 364 - 8, 15.07.2015

Bekir Tasdemir , Zeki Dostbil Kemal Unal Sule Yildirim Ayse Akatli

Öz

If a suspicious finding for primary site of an unknown primary tumor (UPT) is found in limited whole-body FDG PET/CT imaging area, imaging of lower extremities is generally not performed in routine practice. This approach may not be true. In this case, FDG PET/CT imaging was performed in patient with UPT. The limited whole-body FDG PET/CT images showed an increased FDG uptake in a thyroid nodule which was seemed to be a primary lesion at first sight. But similar FDG PET/CT findings might be observed in benign thyroid nodules. So we also acquired FDG PET/CT images of the lower extremities. Then, a mass showing increased FDG uptake was seen in the left thigh. On histopathologic examination, the thyroid nodule was found to be benign and the left thigh mass was diagnosed with a malignant (hemangiopericytoma). This case demonstrates contribution of lower extremity FDG PET/CT imaging to detection of primary site of UPTs in suspected situations.

Anahtar Kelimeler

Positron emission tomography, unknown primary tumor, field of view, lower extremity, hemangiopericytoma

The significance of lower extremity FDG PET/CT imaging in patients with unknown primary tumor

Öz

Kaynakça

• Park JS, Yim JJ, Kang WJ, et al. Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes 2011;4:56
• Fizazi K, Culine S. Metastatic carcinoma of unknown origin. Bull Cancer 1998;85:609-617.
• Kwee TC, Basu S, Cheng G, Alavi A. FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 2010;37:635-644.
• Osman MM, Chaar BT, Muzaffar R, et al. 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique. AJR Am J Roentgenol 2010;195:1397-1403.
• Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-895.
• Abdelmalik AG, Alenezi S, Muzaffar R, Osman MM. The Incremental Added Value of Including the Head in (18)F-FDG PET/CT Imaging for Cancer Patients. Front Oncol 2013;3:71.
• Lee HY, Lee KS, Kim BT, et al. Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci 2009;24:1132-1138.
• Nguyen NC, Chaar BT, Osman MM. Prevalence and patterns of soft tissue metastasis: detection with true whole-body F-18 FDG PET/CT. BMC Med Imaging 2007;7:8.
• Sebro R, Mari-Aparici C, Hernandez-Pampaloni M. Value of true whole-body FDG PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis. Acta Radiol 2013;54:534-539
• Bochev P, Klisarova A, Kaprelyan A, et al. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Hell J Nucl Med 2012;15:125-129.
• Kitajima K, Nakamoto Y, Okizuka H, et al. Accuracy of whole-body FDG PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 2008;22:595-602.
• Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003;226:181-187.
• Posther KE, McCall LM, Harpole DH Jr, et al. Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. J Nucl Med 2006;47:1607-1611.
• Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumor PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181-200.
• ACR-SPR practice guideline for performing FDG PET/CT in oncology. American College of Radiology Web site. http://www.acr.org/~/media/71B746780F934F6D8A1BA5CCA5167EDB.pdf Accessed 06 Jan 2015.